Previous 10 | Next 10 |
The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ). The firm’s ongoing investigation concerns whether Regeneron and/...
2024-05-16 07:15:00 ET Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others. Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have historically been i...
2024-05-14 12:42:09 ET Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference May 14, 2024 9:00 AM ET Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Chris Fenimore - Senior VP of F...
2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell ...
2024-05-08 15:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-08 08:15:41 ET Regeneron ( NASDAQ: REGN ) announced Wednesday that a child who received its gene therapy candidate DB-OTO improved hearing to normal levels within 24 weeks in a Phase 1/2 trial for genetically linked deafness.... Read the full article on Seeking Alpha ...
2024-05-07 09:01:37 ET Apple ( NASDAQ: AAPL ) recently updated its capital return plan by adding a $110B to its buyback program. According to data highlighted by Mizuho, this massive buyback program is larger than 84% of the stocks that sit inside the S&P 500.... Read ...
2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...
2024-05-05 15:10:28 ET More on the markets S&P 500 1%+ Gaps Higher SPY: Don't Buy The Dip Just Yet Rate Hike Unlikely: Expect S&P 500 To Rally To New All-Time Highs Data Insight: April's jobs report was biggest disappointment in at least 2 years ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...